Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies

M Page, E. I. Ekinci, R. M. Jones, P. W. Angus, P. J. Gow, R. C. O'Brien

    Research output: Contribution to journalArticleResearchpeer-review

    Abstract

    Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options. 

    Original languageEnglish
    Pages (from-to)601-604
    Number of pages4
    JournalInternal Medicine Journal
    Volume44
    Issue number6
    DOIs
    Publication statusPublished - Jun 2014

    Fingerprint

    Hyperlipoproteinemia Type II
    Blood Component Removal
    LDL Lipoproteins
    Liver Transplantation
    Lipids
    LDL Receptors
    Pharmaceutical Preparations
    LDL Cholesterol
    Coronary Artery Disease
    Transplantation
    Safety
    Therapeutics

    Cite this

    Page, M ; Ekinci, E. I. ; Jones, R. M. ; Angus, P. W. ; Gow, P. J. ; O'Brien, R. C. / Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. In: Internal Medicine Journal. 2014 ; Vol. 44, No. 6. pp. 601-604.
    @article{283697a1f01a41b7a301553c29ec2dea,
    title = "Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies",
    abstract = "Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options. ",
    keywords = "acetylsalicylic acid, atenolol, atorvastatin, cholesterol, ezetimibe, fenofibrate, isosorbide mononitrate, low density lipoprotein cholesterol, low density lipoprotein receptor, mycophenolic acid 2 morpholinoethyl ester, prednisolone, rosuvastatin, tacrolimus, warfarin, antilipemic agent, azetidine derivative, heptanoic acid derivative, low density lipoprotein, pyrrole derivative, angina pectoris, angiocardiography, aorta stenosis, aorta valve replacement, apheresis, article, bypass surgery, cadaver donor, case report, cholesterol blood level, clinical effectiveness, coronary artery bypass graft, coronary artery disease, drug dose increase, exon, familial hypercholesterolemia, gene, genetic variability, heterozygosity, homozygosity, human, human tissue, liver biopsy, liver function test, liver graft rejection, liver transplantation, low density lipoprotein receptor gene, male, mitral valve replacement, patient safety, postoperative complication, priority journal, pulmonary valve replacement, Ross procedure, stress echocardiography, xanthoma, adult, blood, consanguinity, Coronary Disease, deficiency, diet therapy, drug combination, genetics, Heart Valve Diseases, heart valve replacement, homozygote, Hyperlipoproteinemia Type II, multimodality cancer therapy, Adult, Azetidines, Blood Component Removal, Cholesterol, LDL, Combined Modality Therapy, Consanguinity, Coronary Artery Bypass, Drug Therapy, Combination, Fenofibrate, Heart Valve Prosthesis Implantation, Heptanoic Acids, Homozygote, Humans, Hypolipidemic Agents, Lipoproteins, LDL, Liver Transplantation, Male, Pyrroles, Receptors, LDL",
    author = "M Page and Ekinci, {E. I.} and Jones, {R. M.} and Angus, {P. W.} and Gow, {P. J.} and O'Brien, {R. C.}",
    year = "2014",
    month = "6",
    doi = "10.1111/imj.12444",
    language = "English",
    volume = "44",
    pages = "601--604",
    journal = "Internal Medicine Journal",
    issn = "1444-0903",
    publisher = "Wiley-Blackwell",
    number = "6",

    }

    Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies. / Page, M; Ekinci, E. I.; Jones, R. M.; Angus, P. W.; Gow, P. J.; O'Brien, R. C.

    In: Internal Medicine Journal, Vol. 44, No. 6, 06.2014, p. 601-604.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Liver transplantation for the treatment of homozygous familial hypercholesterolaemia in an era of emerging lipid-lowering therapies

    AU - Page, M

    AU - Ekinci, E. I.

    AU - Jones, R. M.

    AU - Angus, P. W.

    AU - Gow, P. J.

    AU - O'Brien, R. C.

    PY - 2014/6

    Y1 - 2014/6

    N2 - Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options. 

    AB - Homozygous familial hypercholesterolaemia (FH) causes severe premature coronary artery disease because of very high levels of low density lipoprotein (LDL)-cholesterol. Standard lipid-lowering drugs and LDL-apheresis may not be sufficiently effective. Liver transplantation replaces defective LDL receptors and vastly improves the lipid profile, and we present the first report of an Australian adult to receive this treatment. Emerging drug treatments for FH may be alternatives to LDL-apheresis and transplantation, but long-term safety and efficacy data are lacking for all of these options. 

    KW - acetylsalicylic acid

    KW - atenolol

    KW - atorvastatin

    KW - cholesterol

    KW - ezetimibe

    KW - fenofibrate

    KW - isosorbide mononitrate

    KW - low density lipoprotein cholesterol

    KW - low density lipoprotein receptor

    KW - mycophenolic acid 2 morpholinoethyl ester

    KW - prednisolone

    KW - rosuvastatin

    KW - tacrolimus

    KW - warfarin

    KW - antilipemic agent

    KW - azetidine derivative

    KW - heptanoic acid derivative

    KW - low density lipoprotein

    KW - pyrrole derivative

    KW - angina pectoris

    KW - angiocardiography

    KW - aorta stenosis

    KW - aorta valve replacement

    KW - apheresis

    KW - article

    KW - bypass surgery

    KW - cadaver donor

    KW - case report

    KW - cholesterol blood level

    KW - clinical effectiveness

    KW - coronary artery bypass graft

    KW - coronary artery disease

    KW - drug dose increase

    KW - exon

    KW - familial hypercholesterolemia

    KW - gene

    KW - genetic variability

    KW - heterozygosity

    KW - homozygosity

    KW - human

    KW - human tissue

    KW - liver biopsy

    KW - liver function test

    KW - liver graft rejection

    KW - liver transplantation

    KW - low density lipoprotein receptor gene

    KW - male

    KW - mitral valve replacement

    KW - patient safety

    KW - postoperative complication

    KW - priority journal

    KW - pulmonary valve replacement

    KW - Ross procedure

    KW - stress echocardiography

    KW - xanthoma

    KW - adult

    KW - blood

    KW - consanguinity

    KW - Coronary Disease

    KW - deficiency

    KW - diet therapy

    KW - drug combination

    KW - genetics

    KW - Heart Valve Diseases

    KW - heart valve replacement

    KW - homozygote

    KW - Hyperlipoproteinemia Type II

    KW - multimodality cancer therapy

    KW - Adult

    KW - Azetidines

    KW - Blood Component Removal

    KW - Cholesterol, LDL

    KW - Combined Modality Therapy

    KW - Consanguinity

    KW - Coronary Artery Bypass

    KW - Drug Therapy, Combination

    KW - Fenofibrate

    KW - Heart Valve Prosthesis Implantation

    KW - Heptanoic Acids

    KW - Homozygote

    KW - Humans

    KW - Hypolipidemic Agents

    KW - Lipoproteins, LDL

    KW - Liver Transplantation

    KW - Male

    KW - Pyrroles

    KW - Receptors, LDL

    UR - http://www.scopus.com/inward/record.url?scp=84904642201&partnerID=8YFLogxK

    U2 - 10.1111/imj.12444

    DO - 10.1111/imj.12444

    M3 - Article

    VL - 44

    SP - 601

    EP - 604

    JO - Internal Medicine Journal

    JF - Internal Medicine Journal

    SN - 1444-0903

    IS - 6

    ER -